Company Overview and News
There's one commodity that's down three quarters from its 2011 level, and even more from its 2007 peak. But it appears to have found a base, moving sideways for the last year. With supply being slashed and steadily growing demand, it has the potential to rocket in future. The commodity in question is uranium.
SASKATOON, Saskatchewan, 17 mai 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) annonce l’élection de 10 commissaires lors de sa réunion annuelle qui s’est tenue le 16 mai 2018.
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (the “Company” or “Purepoint”) (TSX:PTU.V) today approved the issuance of a total of 3,150,000 options to its Board of Directors, management and certain staff members pursuant to the Company’s stock option plan. The options vest immediately, are exercisable at a price of $0.06 per common share and expire on a date that is five years from the date of grant.
SASKATOON, Saskatchewan, May 16, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) has announced the election of 10 board members at its annual meeting held on May 16, 2018.
TORONTO, May 14, 2018 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (the “Company” or “Purepoint”) (TSX.V:PTU) today announced the results of the latest winter program at its Hook Lake Project, a joint venture between Cameco Corporation (39.5%), Orano Canada Inc. (39.5%) and Purepoint (21%) in the Patterson Uranium District, Saskatchewan Canada.
While every other US auto manufacturer reported a decline in sales for April, Fiat Chrysler reported gains and smashed estimates.
For the past seven years, Uranium prices have been suppressed due to an imbalance of supply and demand.
VANCOUVER, British Columbia, May 09, 2018 (GLOBE NEWSWIRE) -- Blue Sky Uranium Corp. (TSX-V:BSK) (FSE:MAL2) (OTC:BKUCF) ("Blue Sky" or the "Company") is pleased to report it has engaged Chuck Edwards P.Eng. as a technical advisor to assist the Company in planning and managing beneficiation (upgrading) and metallurgical studies and process design for the Ivana Uranium-Vanadium deposit and the Amarillo Grande project.
VANCOUVER, British Columbia, May 07, 2018 (GLOBE NEWSWIRE) -- AZARGA URANIUM CORP. (TSX:AZZ) (FRA:P8AA) (OTCMKTS:PWURF) (“Azarga Uranium”) and URZ ENERGY CORP. (TSX-V:URZ) (OTCQB:URZZF) (“URZ Energy”) are pleased to announce the execution of a definitive arrangement agreement (“Arrangement Agreement”) pursuant to which Azarga Uranium and URZ Energy will merge to form a new US-focused in-situ recovery (“ISR”) uranium development company (the “Transaction”).
Fundamentally, the bull case for uranium is that Uranium prices have been depressed due to post-Fukushima negative sentiment towards nuclear power despite rising demand in emerging markets. Uranium miners have been trading near lows as cheaper crude oil prices subdued immediate pressure for energy importers to switch to alternatives. Nonetheless, the fundamental developments for uranium prices have been very positive and likely are the catalyst for a turnaround in uranium prices.
Discussion of the Global X Uranium ETF, an ETF providing investors access to a broad range of uranium mining companies.
Thank you for standing by. This is the conference operator. Welcome to the Cameco Corporation First Quarter 2018 Results Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions] I would now like to turn the conference over to Rachelle Girard, Director of Investor Relations.
The following slide deck was published by Cameco Corporation in conjunction with their 2018 Q1 earnings call.
14m - Asif
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
as of ET